Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

已收盘 07-27 16:00:00 EDT

5.70

+0.22

+4.01%

盘后5.70

+0.000.00%

19:34 EDT

最高5.94	最低5.47	成交量118.14万
今开5.49	昨收5.48	日振幅8.67%
总市值1.78亿	流通市值9,620万	总股本3,129万
成交额675.41万	换手率7.00%	流通股本1,688万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":5.7,"timestamp":1785182400000,"preClose":5.48,"halted":0,"volume":1181399,"hourTrading":{"tag":"盘后","latestPrice":5.7,"preClose":5.7,"latestTime":"19:34 EDT","volume":5268,"amount":30091.63,"timestamp":1785195248383,"change":0,"changeRate":0,"amplitude":0.027193},"delay":0,"changeRate":0.040145985401459805,"floatShares":16877700,"shares":31289969,"eps":-3.661292,"marketStatus":"已收盘","change":0.22,"latestTime":"07-27 16:00:00 EDT","open":5.49,"high":5.94,"low":5.465,"amount":6754052.176005,"amplitude":0.086679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.661292,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785225600000},"marketStatusCode":5,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":5.48,"preHourTrading":{"tag":"盘前","latestPrice":5.49,"preClose":5.48,"latestTime":"09:29 EDT","volume":537,"amount":2988.9284139,"timestamp":1785158999516,"change":0.01,"changeRate":0.001825,"amplitude":0.122263},"postHourTrading":{"tag":"盘后","latestPrice":5.7,"preClose":5.7,"latestTime":"19:34 EDT","volume":5268,"amount":30091.63,"timestamp":1785195248383,"change":0,"changeRate":0,"amplitude":0.027193},"volumeRatio":1.243702,"impliedVol":1.4222,"impliedVolPercentile":0.8685},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2654036699","title":"美股异动 | CRISPR基因编辑公司Scribe Therapeutics(SCTX.US)登陆美股市场 开盘后涨超59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654036699?lang=zh_cn&edition=full","pubTime":"2026-07-24 23:57","pubTimestamp":1784908651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4539","CRSP","BK4611","KOMP","GNOM","LU1861558580.USD","DTEC","BMED","XT","LU1861559042.SGD","IDNA","HELX","BK4556","NBDS","TARK","WDNA","BK4007","SCTX","LENZ","ARKG","BK4585","FWD","SYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653751229","title":"Summit Therapeutics美股盘前跌超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653751229","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653751229?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:36","pubTimestamp":1784716593,"startTime":"0","endTime":"0","summary":"Summit Therapeutics美股盘前跌超11%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817433621.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817433621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298740","title":"小分子抗癌疗法开发商BlossomHill Therapeutics(BLSM.US)申请美股上市 拟筹资至多1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298740","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652298740?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:20","pubTimestamp":1784532012,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BlossomHill Therapeutics是一家管线已推进至二期临床阶段的生物技术企业，专注于开发小分子抗癌疗法。该公司于上周五向美国证券交易委员会递交招股书，拟通过首次公开募股募资至多1亿美元。BlossomHill Therapeutics专注研发小分子抗癌药物：先找出现有疗法的结构缺陷，再设计新的化合物来克服这些缺陷。BlossomHill Therapeutics于2026年4月24日秘密提交了上市申请。摩根大通、Leerink Partners、Guggenheim Securities、LifeSci Capital和HC Wainwright是此次交易的联合承销商。定价条款未披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298685","title":"缺氧疗法生物科技公司NuvOx Therapeutics(NUOX.US)申请美股IPO，拟募资2000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652298685?lang=zh_cn&edition=full","pubTime":"2026-07-20 14:55","pubTimestamp":1784530507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4539","BK4581","FRHC","AGNG","KCE","LENZ","BK4127","IPOS","XBI","BK4585","BK4139","GDOC","BK4588","MEDX","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182696709","title":"新闻稿：Glucotrack与Lōkahi Therapeutics完成战略业务合并，建立Lōkahi控制的公开平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1182696709","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182696709?lang=zh_cn&edition=full","pubTime":"2026-07-15 05:45","pubTimestamp":1784065528,"startTime":"0","endTime":"0","summary":"Glucotrack, Inc.今日宣布，其与Lōkahi Therapeutics的战略业务合并已正式完成。本次交易的结构设计使得Lōkahi Therapeutics成为合并后公司的运营及控制主体，并利用Glucotrack的公开市场平台来支持长期增长及资本获取。在交易完成之际，Lōkahi Therapeutics的证券持有人获得了Glucotrack普通股与可转换优先股的组合。届时，在完全稀释基础上，并受交易相关融资及常规调整影响，Lōkahi Therapeutics的证券持有人将持有合并后公司约90%的股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GCTK","LENZ","BK4139","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651174232","title":"信达生物与 Spero Therapeutics就IBI355（第三代抗CD40L单抗，临床II期准备阶段）达成独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2651174232","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651174232?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:00","pubTimestamp":1784023200,"startTime":"0","endTime":"0","summary":"Spero计划于2027年第二季度启动IBI355治疗IgG4-RD患者的临床II期研究；信达生物计划于2027年初前在中国启动IBI355治疗SjD的临床II期研究。我们非常高兴与Spero Therapeutics达成合作，共同推进IBI355的全球开发。结合信达生物和Spero Therapeutics在自身免疫领域的临床资源和专注投入，我们将共同加速这一差异化疗法的研发进程，致力于为慢性病患者带来新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5003988_ZH03988_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5003988_ZH03988_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2097828805.USD","BK1161","KURE","HK0000165453.HKD","LU2242644610.SGD","LU2097828631.EUR","LU2097828557.USD","LU2097828474.EUR","BK4539","LU2097828714.EUR","LU0502904849.HKD","LU0455707207.USD","BK1589","LU2328871848.SGD","LU1969619763.USD","BK1583","LU2488822045.USD","BK4139","BK4007","LENZ","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651722111","title":"Stoke Therapeutics任命Thomas McCauley博士为首席科学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2651722111","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651722111?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:49","pubTimestamp":1783946940,"startTime":"0","endTime":"0","summary":"生物技术公司Stoke Therapeutics近日宣布，任命Thomas McCauley博士为首席科学官，负责领导公司的科学战略，并推动其基于RNA药物平台的管线扩展与临床推进。他曾担任Neptune Bio的总裁兼首席执行官，并先后在Omega Therapeutics、Macrolide Pharmaceuticals和Translate Bio担任首席科学官。　　Stoke Therapeutics专注于利用其专有的TANGO技术开发反义寡核苷酸药物，以选择性恢复蛋白质水平。Stoke与渤健已就此药物建立战略合作，共同进行开发和商业化。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-13/doc-inihsisy8947593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183275253","title":"Pliant Therapeutics任命Flavia Borellini博士和Robert Iannone博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1183275253","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183275253?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:35","pubTimestamp":1783946106,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Pliant Therapeutics今日宣布，任命Flavia Borellini博士与Robert Iannone博士为公司董事会新成员。这两项任命为董事会注入了深厚的全球肿瘤药物开发经验，并进一步强化了其在运营与监管事务方面的专业能力。目前，除了在Pliant任职外，他还担任Autolus Therapeutics的董事会成员。关于Pliant Therapeutics, Inc.：Pliant Therapeutics是一家临床阶段的生物制药公司，专注于基于整合素的疗法的发现与开发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","LENZ","BK4585","BK4139","BK4588","R","BK4539","IBB","BK4007","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924739","title":"Cardiol Therapeutics将出席B. Riley Mind, Muscle & Vision峰会炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924739","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650924739?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:54","pubTimestamp":1783601672,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc．宣布，将参加于2026年7月16日在波士顿举行的B． Riley Securities Mind， Muscle & Vision Summit，并在当日下午12：20进行炉边谈话。　　此次峰会为B． Riley Securities主办的单一医疗健康会议，聚焦神经学、肌肉及眼科疾病领域的创新成果。　　Cardiol Therapeutics是一家处于后期阶段的生命科学公司，专注于推进心脏疾病抗炎和抗纤维化疗法的开发。　　Cardiol目前正在推进MAVERIC项目，评估CardiolRx治疗复发性心包炎的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-09/doc-inihfihx8573744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649858622","title":"Incyte(INCY)以12.5亿美元完成收购Vega Therapeutics 拓宽血液学管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2649858622","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649858622?lang=zh_cn&edition=full","pubTime":"2026-07-06 21:19","pubTimestamp":1783343950,"startTime":"0","endTime":"0","summary":"根据双方此前达成的股票购买协议，Incyte已支付12.5亿美元的预付款，收购了Vega Therapeutics的全部发行在外股份。此外，Star Therapeutics未来还有权获得最高达7.5亿美元的商业销售里程碑付款。通过本次收购，Incyte成功将Vega的核心资产——创新单克隆抗体VGA039收入囊中。目前，该药物正在全球开展一项名为VIVID-6的单臂交叉3期临床试验，以评估其在各类血管性血友病患者中的安全性和有效性。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302236","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","INCY","BK4588","LENZ","BK4539","BK4007","BK4550","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183410479","title":"Lenz Therapeutics推出新型远程医疗处方方案，加速老花眼患者获取Vizz®治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1183410479","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183410479?lang=zh_cn&edition=full","pubTime":"2026-07-06 20:22","pubTimestamp":1783340531,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics宣布推出一种新型远程医疗处方方案，旨在加速老花眼患者获取Vizz®治疗。此举将简化患者的治疗流程，提高治疗的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649197641","title":"生物技术公司Scribe Therapeutics(SCTX.US)申请美股IPO 拟筹资至多7500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649197641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649197641?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:30","pubTimestamp":1783323045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4127","FRHC","BK4539","WDNA","BK4007","IPOS","BK4139","KCE","LENZ","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648509782","title":"联合治疗公司以1.4亿美元现金收购生物技术公司Thymmune Therapeutics。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648509782","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648509782?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:31","pubTimestamp":1782988300,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647426551","title":"Unicycive Therapeutics股价下跌45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647426551","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647426551?lang=zh_cn&edition=full","pubTime":"2026-06-30 21:32","pubTimestamp":1782826373,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics股价下跌45.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788649482.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788649482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","LENZ","BK4539","UNCY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647232807","title":"益普生将以最高17.5亿美元收购Kartos Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2647232807","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647232807?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:20","pubTimestamp":1782710416,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158361816","title":"Lenz Therapeutics与Arrotex Pharmaceuticals就Vizz™在澳大利亚和新西兰达成独家许可与商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1158361816","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158361816?lang=zh_cn&edition=full","pubTime":"2026-06-24 20:32","pubTimestamp":1782304365,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics与Arrotex Pharmaceuticals宣布，双方已就Vizz™在澳大利亚和新西兰市场达成一项独家许可与商业化合作协议。该协议的签署标志着两家公司将在上述区域共同推进Vizz™的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645889615","title":"Definium Therapeutics(DFTX)宣布7亿美元增发公开募股定价 每股34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645889615","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645889615?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:11","pubTimestamp":1782292315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 临床后期生物制药公司Definium Therapeutics 正式宣布，其已完成扩大规模的包销公开发行定价，公司将以每股34.00美元的价格公开发行20,588,236股普通股。在不扣除承销折扣、佣金及其他发行费用的情况下，Definium预计此次公开发行的募资总额将达到约7亿美元。本次发行预计将于2026年6月25日左右交割。而就在本次发行定价前不久，Definium刚于6月22日宣布，其用于治疗重度抑郁症的创新疗法“DT120口崩片”在3期临床研究中取得了积极的顶线结果。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301833","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UUP","BK4139","LENZ","DFTX","BK4539","BK4007","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645685014","title":"德琪医药-B(06996)与MPM BioImpact创立的K2 Therapeutics就ATG-106达成独家授权协议 并授予其一项未披露双特异性TCE的选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2645685014","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645685014?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:36","pubTimestamp":1782088596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，Antengene Biologics Limited与由K2 Therapeutics新成立的一家公司， 已就ATG-106订立一份独家且可再授权的授权协议。此外， K2与授权方亦已订立一份选择权协议，据此，K2已获授一项独家选择权，以取得一款未披露的临床前双特异性TCE候选药物的独家授权。MPM BioImpact是一家全球领先的生物技术投资机构，拥有逾30年创建及投资创新公司的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK4007","BK4539","BK1191","BK1583","BK1574","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642382782","title":"Viking Therapeutics任命Hubert C. Chen博士为新任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=2642382782","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642382782?lang=zh_cn&edition=full","pubTime":"2026-06-11 23:06","pubTimestamp":1781190360,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Viking Therapeutics周四宣布，任命Hubert C． Chen博士为首席医疗官。Chen博士将负责领导公司的临床开发、医学及监管事务，直接向公司总裁兼首席执行官Brian Lian博士汇报。在加入Viking之前，他曾担任Loyal Animal Health的首席研发官，领导了首个与美国食品药品监督管理局达成谈判的长寿疗法有效性和安全性要求制定工作。　　这一任命正值Viking推进其核心候选药物VK2735的关键时期。Viking还计划于本季度启动新型胰淀素激动剂VK3019的一期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaenm0642884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159891","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169652203","title":"Lenz宣布与云顶新耀达成协议，后者获Vizz®(Lnz100)大中华区开发及商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1169652203","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169652203?lang=zh_cn&edition=full","pubTime":"2026-06-08 07:31","pubTimestamp":1780875098,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics公司宣布，已与Everest Medicines（云顶新耀）达成授权协议。根据协议，云顶新耀获得了在大中华区（包括中国大陆、香港、澳门及台湾）开发和商业化Vizz®（研发代号Lnz100）的独家权利。\n该交易标志着Lenz的核心产品管线进入了重要的亚太市场。Vizz®（Lnz100）是一款处于研发阶段的创新疗法，此次合作将加速该产品在广阔的大中华区的临床开发与未来市场准入。\n通过此次授权，Lenz有望获得包括首付款、里程碑付款以及基于未来销售额的特许权使用费在内的潜在收益。云顶新耀则将凭借其在本地区的开发与商业化能力，推动该产品的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.0579},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.4158},{"period":"6month","weight":-0.7319},{"period":"1year","weight":-0.8359},{"period":"ytd","weight":-0.6575}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.038365},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}